香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 截至二零二三年十二月三十一日止年度的 年度業績公告 董事會欣然宣佈本集團截至二零二三年十二月三十一日止年度的經審核綜合 年 度 業 績，連 同 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 的 比 較 數 字 如 下。本 集團於報告期間的綜合財務報表已由本集團核數師安永會計師事務所進行審 核，並 經 由 本 公 司 管 理 層 及 審 核 委 員 會 審 閱。 | --- | --- | --- | --- | |--------------------------|-- ...

寧波健世科技股份有限公司 Jenscare Scientific Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 9877 2023 中期報告 目錄 2 釋義 4 公司資料 6 財務摘要 7 業務摘要 9 管理層討論及分析 18 其他資料 26 獨立核數師報告 27 中期簡明綜合損益及其他全面收益表 28 中期簡明綜合財務狀況表 29 中期簡明綜合權益變動表 30 中期簡明綜合現金流量表 31 中期簡明綜合財務報表附註 2 2023年中期報告 寧波健世科技股份有限公司 釋義 於本中期報告內，除文義另有所指外，下列詞彙具有以下所載涵義。 | --- | --- | --- | |------------------------------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 截至二零二三年六月三十日止六個月的 中期業績公告 董 事 會 欣 然 宣 佈 本 集 團 於 報 告 期 間 的 未 經 審 核 綜 合 中 期 業 績，連 同 二 零 二 二 年 同 期 的 比 較 數 字。本 集 團 於 報 告 期 間 的 未 經 審 核 綜 合 財 務 報 表 已 由 審 核 委 員 會 及 本 公 司 核 數 師 審 閱。 | --- | --- | --- | --- | |-----------------------------------|---------- ...

Company Overview - The company was listed on October 10, 2022, with H shares available for trading on the Hong Kong Stock Exchange[4]. - The core products include LuX-Valve and Ken-Valve, which are defined under the listing rules[4]. - The company has successfully listed on the Hong Kong Stock Exchange, providing a solid foundation for ongoing product innovation and international strategy[11]. Financial Performance - The company reported a loss before tax of RMB 440.914 million for the fiscal year ending December 31, 2022, compared to a loss of RMB 500.673 million in 2021[18]. - Other income and gains increased from RMB 8.9 million in 2021 to RMB 54.4 million in 2022, primarily due to currency exchange gains and additional government subsidies[48]. - R&D expenses rose from RMB 265.3 million in 2021 to RMB 291.6 million in 2022, driven by increased employee costs and third-party contract costs[49]. - Administrative expenses decreased from RMB 238.5 million in 2021 to RMB 219.7 million in 2022, mainly due to a reduction in share-based compensation expenses[51]. - The company reported a net loss of RMB 500.7 million in 2021 and RMB 440.9 million in 2022, with no income tax provision due to lack of taxable profit[56]. - Cash and cash equivalents decreased by 9.1% from RMB 800.6 million at the end of 2021 to RMB 727.4 million at the end of 2022[56]. - The company’s net cash used in investing activities was RMB 146.6 million in 2022, primarily for property and equipment purchases[56]. - Capital expenditures increased from RMB 15.4 million in 2021 to RMB 49.6 million in 2022, primarily due to the purchase of machinery, office equipment, and leasehold improvements[57]. Market Strategy and Growth - The company aims to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[6]. - A strategic acquisition is planned to enhance technological capabilities, with an estimated investment of $50 million[6]. - The company expects revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion[6]. - The company aims to accelerate the commercialization of its core products in the growing transcatheter tricuspid valve replacement market[47]. - The company plans to expand its international presence to become an industry leader in structural heart disease treatment[47]. Research and Development - Research and development efforts are focused on enhancing product features and expanding the product line, with a budget allocation of 15% of total revenue for R&D[6]. - The company has 12 products in various stages of development, including 4 core products in the transcatheter heart valve category[29]. - The company expects to launch 1-2 significant products annually starting in 2023, ensuring continuous innovation and commercialization[15]. - LuX-Valve received registration submission to the National Medical Products Administration (NMPA) in December 2022, with commercialization expected in Q3 2023[32]. - The company has initiated early feasibility clinical trials for the LuX-Valve Plus product in France, Germany, Spain, and Switzerland, and has also started trials in the US and Canada[11]. - The company is advancing its confirmatory clinical trial for the mitral valve repair device JensClip, with completion expected by the end of 2023[12]. - Ken-Valve, a first-generation transcatheter aortic valve replacement system, completed its confirmatory clinical trial in March 2023, with commercialization approval anticipated in H1 2024[34]. Corporate Governance - The company has adopted the corporate governance code as per the listing rules, with a commitment to reviewing its governance structure regularly[92]. - The board consists of two executive directors, four non-executive directors, and three independent non-executive directors, ensuring a strong level of independence[92]. - The company emphasizes the importance of separating the roles of Chairman and CEO, although currently, Mr. Lu holds both positions, which the board believes benefits management[92]. - The company has a diverse board with members holding advanced degrees in finance, economics, and engineering from prestigious institutions[78]. - The board is responsible for overseeing major company affairs, including policy formulation, overall strategy, and risk management systems[94]. Environmental, Social, and Governance (ESG) Initiatives - The company has implemented measures to reduce carbon emissions and enhance energy management as part of its ESG strategy[151]. - The company’s environmental performance report adheres to the guidelines set by the Hong Kong Stock Exchange, ensuring transparency and accuracy in its disclosures[148]. - The company aims to achieve a 10% reduction in electricity consumption, a 5% reduction in water usage, and a 10% reduction in oil consumption in 2023[174]. - The company has established a waste management system to ensure compliance with environmental regulations and to minimize waste generation[169]. - The company’s mission includes providing safe and effective treatment solutions, reflecting its commitment to corporate social responsibility[150]. Employee Management and Development - The company has established a performance management system that includes monthly, quarterly, semi-annual, and annual assessments[179]. - The employee demographic shows that 60.3% are female, and 52.7% hold a university degree or higher[182]. - The company provides competitive compensation packages, including basic salary, stock options, and various allowances[180]. - The company has established a comprehensive employee health and safety management system, achieving ISO14001 and ISO45001 certifications[189]. - The company conducts regular safety training to enhance employee awareness of production risks[190].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 截至二零二二年十二月三十一日止年度的 年度業績公告 董事會欣然宣佈本集團截至二零二二年十二月三十一日止年度的經審核綜合 業 績，連 同 截 至 二 零 二 一 年 十 二 月 三 十 一 日 止 年 度 的 比 較 數 字 如 下。本 集 團 綜 合財務報表已由本集團核數師安永會計師事務所根據國際財務報告準則進行 審 核，並 經 由 本 公 司 管 理 層 及 審 核 委 員 會 審 閱。 | --- | --- | --- | --- | |----------------------------------------------|---------- ...